Health TrialsbyHealthPanel

Efficacy and Safety of 675-nm Laser for Dorsal Hand Rejuvenation

ConditionWrinkle
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-65
SponsorMahidol University

About this trial

This study aimed to evaluate efficacy and safety of 675-nm laser for dorsal hand rejuvenation in Thai patients. Twenty-six subjects aged 50 to 65 years diagnosed with wrinkle and solar lentigines on both dorsums of hands were included and treated with RedTouch for 3 times every 4 weeks. Then, they were follow up at 3 and 6 months after the final treatment. The measurement of 5-point Global Aesthetic Improvement Scale scores by physicians and subjects were conducted. Moreover, pigmentation level, wrinkle and texture were also recored using Antera. Elasticity was measured using Cutometer.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects diagnosed with wrinkles and solar lentigines on both dorsum of hands

Disqualifiers

Pregnant or lactation

Sugjects with a history of allergy to near-infrared wavelength or photosensitizing agents

Subjects who have been treated with any kind of energy-based device on both dorsum of hands 6 months prior to the inclusion

Subjects who have been injected with filler, or platelet-rich plasma on both dorsum of hands on their faces 6 months prior to the inclusion

Trial design

Design model

Single group

Treatments tested in this trial

  • Redtouch

    Device

    675-nm laser

Treatment groups

26 Participants
are divided into 1 treatment group
Group A: 675-nm laser (RedTouch)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The change in pigmentation level, wrinkle and texture

Using Antera®

Time frame
Baseline, 4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment

Secondary outcomes

1

The change in elasticity

Using Cutometer®

Time frame
Baseline, 4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment
2

Overall improvement by physicians and patients

5-point GAIS

Time frame
4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment
3

Adverse events

Side effects

Time frame
4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment
4

Pain score

Visual analog scale (0-10; no pain-worst pain possible)

Time frame
Baseline, 4, 8, 12 weeks after the first treatment

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mahidol University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: